EZEmmanuel A. Zavalis

Emmanuel A. Zavalis

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Emmanuel A. Zavalis has a total of 78 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Registration and reporting of clinical trials affiliated with California universities and with primary completion date from 2014 to 2017

    by Mario Malički, Vladislav Nachev, Susanne Wieschowski, Nicole Hildebrand, Stefanie Gestrich, Samruddhi Yerunkar, Emmanuel Zavalis, Benjamin Gregory Carlisle, Delwen L. Franzen, Maia Salholz-Hillel, et al.

    Background: Public information on US clinical trials is shared through the ClinicalTrials.gov registry. This study’s goal was to determine prospective registration, results reporting, trial registration number reporting, and publication accessibility status for trials with primary completion dates from 2014 to 2017 affiliated with seven California universities. Methods: We identified trials with investigators, sponsors, or responsible parties affiliated with seven California universities and searched for their results publications manually. We then used semi-automatic methods to determine prospective registration, summary results reporting in a registry, publication status, and reporting of registration numbers in the abstract and the full text of manuscripts. Results: We identified 1091 unique trials. Most trials were single-center ( n = 752, 69%) and had a median of 50 participants (IQR 21 to 150). Overall, 64% of trials ( n = 698) were prospectively registered, 46% ( n = 500) had summary results reported in the registry, 69% ( n = 750) had results published as articles, and an additional 3% ( n = 36) as abstracts or posters. Results reporting (summary, articles, abstracts or posters) occurred for 58% of trials ( n = 637) within 2 years, and for 81% ( n = 888) within 5 years of the study’s primary completion date. Of journal publications, 77% ( n = 579) were open access publications, 37% ( n = 276) had trial registration numbers listed in their abstract, and 45% ( n = 336) in the manuscript. Only 92 (8%) of these trials were legally required to report results, and only 2 (2%) of those were overdue and under the primary responsibility of a California university to report. Conclusions: Almost one fifth of clinical trials with primary completion dates from 2014 to 2017 with investigators, sponsors or responsible parties affiliated with seven California biomedical research universities lacked any results reporting 5 years after their primary completion, and only 58% reported results within 2 years. Even though a large majority of these trials were completed before US legal mandates for reporting, there was an ethical requirement that the burden to research participants should be commensurate with the scientific value of the research. Research has no public scientific value if its results are not reported.


  • Open Access

    Instability of Global Burden of Disease Estimates of Deaths and DALYs from Major Risk Factors

    by Emmanuel A. Zavalis, Angelo Maria M Pezzullo, John P.A. Ioannidis

    Importance: The Global Burden of Disease (GBD) study provides widely used estimates of mortality and disability-adjusted life years (DALYs) attributable to risk factors. Objective: To evaluate the variability and consistency of GBD risk factor estimates for mortality and DALYs. Data Sources: GBD Risk Factor collaboration estimates extracted from published tables and IHME repository. Study Selection: GBD Risk Factor collaboration publications (2010-2023). Data Extraction and Synthesis: Death and DALY estimates were manually extracted by one reviewer with independent validation of a random sample of 100 by another with no discrepancies. Risk factor naming was harmonized across iterations to ensure comparability; those with inconsistent definitions were excluded. Main Outcomes and Measures: We calculated the fluctuations in deaths and DALYs for each risk factor across GBD iterations for different years (2010-2023), and between the original and subsequently revised estimates for each year (1990-2021) expressed in the ratio of the min-max range to the mean (R/M) and coefficient of variation (CV). We examined in more detail analyses diet and low physical activity. Finally, point estimates were compared to the previous iterations’ estimates 95% uncertainty intervals (95%UI) for GBD 2019, 2021 and 2023. Results: Across GBD iterations from 2010 to 2023, the median R/M was 0.8 (range, 0–3.8) for deaths, and 0.7 (range, 0.1–3.3) for DALYs. Among level 2 dietary and child and maternal malnutrition death estimates showed high variability (R/M>1 for 7/16 and 3/8 of risks, respectively). When comparing original estimates with GBD 2019, 2021, and 2023 estimates for the same years, the median R/M was 0.5 (0.0-2.9) for deaths and 0.4 (0-2.9) for DALYs. The CV was above 0.2 for 320/580 (52%) of death and 306/609 of DALY estimates. 70-96% of point estimates for red meat, sugar-sweetened beverages, fruits, vegetables and seafood omega-3 fatty acids in GBD 2021 fell outside the GBD 2019 95%UI. In GBD 2023, only diet high in trans fats had over half of point estimates outside the GBD 2021 95%UI. Conclusions and Relevance: GBD estimates show large instability, particularly for behavioral risks, making them unlikely to simply reflect genuine changes over time, and warranting caution in interpretation. Key Points: Question: How stable and consistent are the Global Burden of Disease (GBD) estimates for mortality and disability-adjusted life years (DALYs) attributable to major risk factors across iterations from 2010 to 2023? Findings: In this study comparing estimates across eight GBD iterations, substantial variability was observed. Behavioral, particularly dietary risks showed the greatest instability. Comparing revised estimates across iterations half the estimates had a coefficient of variation exceeding 0.2. A third of estimates for dietary risks in GBD 2021 fell outside the corresponding GBD 2019 uncertainty intervals. Meaning: GBD risk factor estimates, especially for behavioral and dietary risks, show marked inconsistency likely reflecting methodological or data changes rather than true burden shifts.


  • Open Access

    Registration and Reporting of Clinical Trials Affiliated with California Universities and with Primary Completion Date from 2014 to 2017

    by Mario Malički, Vladislav Nachev, Susanne Wieschowski, Nicole Hildebrand, Stefanie Gestrich, Samruddhi Yerunkar, Emmanuel Zavalis, Benjamin Gregory Carlisle, Delwen L. Franzen, Maia Salholz-Hillel, et al.

    Background Public information on US clinical trials is shared through the ClinicalTrials.gov registry. This study’s goal was to determine prospective registration, results reporting, trial registration number reporting, and publication accessibility status for trials with primary completion dates from 2014 to 2017 affiliated with seven California universities. Methods We identified trials with investigators, sponsors, or responsible parties affiliated with seven California universities and searched for their results publications manually. We then used semi-automatic methods to determine prospective registration, summary results reporting in a registry, publication status, and reporting of registration numbers in the abstract and the full text of manuscripts. Results We identified 1,091 unique trials. Most trials were single-center (n=752, 69%) and had a median of 50 participants (IQR 21 to 150). Overall, 64% of trials (n=698) were prospectively registered, 46% (n=500) had summary results reported in the registry, 69% (n=750) had results published as articles, and an additional 3% (n=36) as abstracts or posters. Results reporting (summary, articles, abstracts or posters) occurred for 58% of trials (n=637) within 2 years, and for 81% (n=888) within 5 years of study primary completion date. Of journal publications, 77% (n=579) were open access publications, 37% (n=276) had trial registration numbers listed in their abstract, and 45% (n=336) in the manuscript. Only 92 (8%) of these trials were legally required to report results, and only 2 (2%) of those were overdue and under primary responsibility of a California university to report. Conclusions Almost one fifth of clinical trials with primary completion dates from 2014 to 2017 with investigators, sponsors or responsible parties affiliated with seven California biomedical research universities lacked any results reporting 5 years after their primary completion, and only 58% reported results within 2 years. Even though a large majority of these trials were completed before US legal mandates for reporting, there was an ethical requirement that the burden to research participants should be commensurate with the scientific value of the research. Research has no public scientific value if its results are not reported.


  • Open Access

    Results reporting for clinical trials led by medical universities and university hospitals in the nordic countries was often missing or delayed

    by Gustav Nilsonne, Susanne Wieschowski, Nicholas J. DeVito, Maia Salholz-Hillel, Love Ahnström, Till Bruckner, Katarzyna Klas, Tarik Suljic, Samruddhi Yerunkar, Natasha Olsson, et al.


  • Open Access

    Difficulties in running clinical trials on physical activity

    by Emmanuel A Zavalis, Pontus Andell

    This commentary refers to ‘Aerobic, resistance, or combined exercise training and cardiovascular risk profile in overweight or obese adults: the CardioRACE trial’, by D.-c. Lee et al., https://doi.org/10.1093/eurheartj/ehad827 and the discussion piece ‘Re-evaluating concurrent training strategies for cardiovascular risk reduction in overweight or obese adults’, by J. Du and J. Hou, https://doi.org/10.1093/eurheartj/ehae583.


  • Open Access

    An evaluation of reproducibility and errors in published sample size calculations performed using G*Power

    by Robert T. Thibault, Emmanuel A. Zavalis, Mario Malički, Hugo Pedder

    Background Published studies in the life and health sciences often employ sample sizes that are too small to detect realistic effect sizes. This shortcoming increases the rate of false positives and false negatives, giving rise to a potentially misleading scientific record. To address this shortcoming, many researchers now use point-and-click software to run sample size calculations. Objective We aimed to (1) estimate how many published articles report using the G*Power sample size calculation software; (2) assess whether these calculations are reproducible and (3) error-free; and (4) assess how often these calculations use G*Power’s default option for mixed-design ANOVAs—which can be misleading and output sample sizes that are too small for a researcher’s intended purpose. Method We randomly sampled open access articles from PubMed Central published between 2017 and 2022 and used a coding form to manually assess 95 sample size calculations for reproducibility and errors. Results We estimate that more than 48,000 articles published between 2017 and 2022 and indexed in PubMed Central or PubMed report using G*Power (i.e., 0.65% [95% CI: 0.62% - 0.67%] of articles). We could reproduce 2% (2/95) of the sample size calculations without making any assumptions, and likely reproduce another 28% (27/95) after making assumptions. Many calculations were not reported transparently enough to assess whether an error was present (75%; 71/95) or whether the sample size calculation was for a statistical test that appeared in the results section of the publication (48%; 46/95). Few articles that performed a calculation for a mixed-design ANOVA unambiguously selected the non-default option (8%; 3/36). Conclusion Published sample size calculations that use G*Power are not transparently reported and may not be well-informed. Given the popularity of software packages like G*Power, they present an intervention point to increase the prevalence of informative sample size calculations.


  • Open Access

    Assessment of transparency indicators in space medicine

    by Rosa Katia Bellomo, Emmanuel A. Zavalis, John P. A. Ioannidis

    Space medicine is a vital discipline with often time-intensive and costly projects and constrained opportunities for studying various elements such as space missions, astronauts, and simulated environments. Moreover, private interests gain increasing influence in this discipline. In scientific disciplines with these features, transparent and rigorous methods are essential. Here, we undertook an evaluation of transparency indicators in publications within the field of space medicine. A meta-epidemiological assessment of PubMed Central Open Access (PMC OA) eligible articles within the field of space medicine was performed for prevalence of code sharing, data sharing, pre-registration, conflicts of interest, and funding. Text mining was performed with the rtransparent text mining algorithms with manual validation of 200 random articles to obtain corrected estimates. Across 1215 included articles, 39 (3%) shared code, 258 (21%) shared data, 10 (1%) were registered, 110 (90%) contained a conflict-of-interest statement, and 1141 (93%) included a funding statement. After manual validation, the corrected estimates for code sharing, data sharing, and registration were 5%, 27%, and 1%, respectively. Data sharing was 32% when limited to original articles and highest in space/parabolic flights (46%). Overall, across space medicine we observed modest rates of data sharing, rare sharing of code and almost non-existent protocol registration. Enhancing transparency in space medicine research is imperative for safeguarding its scientific rigor and reproducibility.


  • Open Access

    Results reporting for clinical trials led by medical universities and university hospitals in the Nordic countries was often missing or delayed

    by Gustav Nilsonne, Susanne Wieschowski, Nicholas J. DeVito, Maia Salholz-Hillel, Love Ahnström, Till Bruckner, Katarzyna Klas, Tarik Suljic, Samruddhi Yerunkar, Natasha Olsson, et al.

    Objective To systematically evaluate timely reporting of clinical trial results at medical universities and university hospitals in the Nordic countries. Study Design and Setting In this cross-sectional study, we included trials (regardless of intervention) registered in the EU Clinical Trials Registry and/or ClinicalTrials.gov, completed 2016-2019, and led by a university with medical faculty or university hospital in Denmark, Finland, Iceland, Norway, or Sweden. We identified summary results posted at the trial registries, and conducted systematic manual searches for results publications (e.g., journal articles, preprints). We present proportions with 95% confidence intervals (CI), and medians with interquartile range (IQR). Protocol: https://osf.io/wua3r Results Among 2,113 included clinical trials, 1,638 (77.5%, 95%CI 75.9-79.2%) reported any results during our follow-up; 1,092 (51.7%, 95%CI 49.5-53.8%) reported any results within 2 years of the global completion date; and 42 (2%, 95%CI 1.5-2.7%) posted summary results in the registry within 1 year. Median time from global completion date to results reporting was 698 days (IQR 1,123). 856/1,681 (50.9%) of ClinicalTrials.gov-registrations were prospective. Denmark contributed approximately half of all trials. Reporting performance varied widely between institutions. Conclusion Missing and delayed results reporting of academically-led clinical trials is a pervasive problem in the Nordic countries. We relied on trial registry information, which can be incomplete. Institutions, funders, and policy makers need to support trial teams, ensure regulation adherence, and secure trial reporting before results are permanently lost. What is new? - Many Nordic registered clinical trials were reported late or not at all. - Almost one in four trials remained unreported at the end of our search period. - About half of registered trials had reported results two years after completion. - Only 2% of trials posted summary results in the registry one year after completion. - Concerted action is needed to improve reporting of Nordic clinical trials.


  • Open Access

    Availability of evidence and comparative effectiveness for surgical versus drug interventions: an overview of systematic reviews and meta-analyses

    by Emmanuel A Zavalis, Anaïs Rameau, Anirudh Saraswathula, Joachim Vist, Ewoud Schuit, John P Ioannidis

    Objectives This study aims to examine the prevalence of comparisons of surgery to drug regimens, the strength of evidence of such comparisons and whether surgery or the drug intervention was favoured. Design Systematic review of systematic reviews (umbrella review). Data sources Cochrane Database of Systematic Reviews. Eligibility criteria Systematic reviews attempt to compare surgical to drug interventions. Data extraction We extracted whether the review found any randomised controlled trials (RCTs) for eligible comparisons. Individual trial results were extracted directly from the systematic review. Synthesis The outcomes of each meta-analysis were resynthesised into random-effects meta-analyses. Egger’s test and excess significance were assessed. Results Overall, 188 systematic reviews intended to compare surgery versus drugs. Only 41 included data from at least one RCT (total, 165 RCTs) and covered a total of 103 different outcomes of various comparisons of surgery versus drugs. A GRADE assessment was performed by the Cochrane reviewers for 87 (83%) outcomes in the reviews, indicating the strength of evidence was high in 4 outcomes (4%), moderate in 22 (21%), low in 27 (26%) and very low in 33 (32%). Based on 95% CIs, the surgical intervention was favoured in 38/103 (37%), and the drugs were favoured in 13/103 (13%) outcomes. Of the outcomes with high GRADE rating, only one showed conclusive superiority in our reanalysis (sphincterotomy was better than medical therapy for anal fissure). Of the 22 outcomes with moderate GRADE rating, 6 (27%) were inconclusive, 14 (64%) were in favour of surgery and 2 (9%) were in favour of drugs. There was no evidence of excess significance. Conclusions Though the relative merits of surgical versus drug interventions are important to know for many diseases, high strength randomised evidence is rare. More randomised trials comparing surgery to drug interventions are needed.


  • Open Access

    Assessment of transparency indicators in Space Medicine

    by Rosa Katia Bellomo, Emmanuel A. Zavalis, John P. A. Ioannidis

    Space medicine is a vital discipline with often time-intensive and costly projects and constrained opportunities for studying various elements such as space missions, astronauts, and simulated environments. Moreover, private interests gain increasing influence in this discipline. In scientific disciplines with these features, transparent and rigorous methods are essential. Here, we undertook an evaluation of transparency indicators in publications within the field of space medicine. A meta-epidemiological assessment of PubMed Central Open Access (PMC OA) eligible articles within the field of space medicine was performed for prevalence of code sharing, data sharing, pre-registration, conflicts of interest, and funding. Text mining was performed with the rtransparent text mining algorithms with manual validation of 200 random articles to obtain corrected estimates. Across 1215 included articles, 39 (3%) shared code, 258 (21%) shared data, 10 (1%) were registered, 110 (90%) contained a conflict-of-interest statement, and 1141 (93%) included a funding statement. After manual validation, the corrected estimates for code sharing, data sharing, and registration were 5%, 27%, and 1%, respectively. Data sharing was 32% when limited to original articles and highest in space/parabolic flights (46%). Overall, across space medicine we observed modest rates of data sharing, rare sharing of code and almost non-existent protocol registration. Enhancing transparency in space medicine research is imperative for safeguarding its scientific rigor and reproducibility.